Introduction
Paraneoplastic autoimmune syndromes include a heterogeneous group of neurological disorders caused by means other than metabolic and nutritional deficits, infections, coagulopathies, metastases, and side effects of cancer treatment. Antigenic proteins derived from the tumors are presumed to be the immunogens initiating the autoimmune responses.
The literature describes a group of paraneoplastic antibodies refered to as anti-neuronal nuclear antibodies (ANNA-1, -2, and -3), which are associated with a variety of syndromes, most notably localized to the cerebellum (Chan et al., 2001; Bataller and Dalmau, 2003; Toothaker and Rubin, 2009 ). The most recently described, ANNA-3, has been associated with sensory and sensorimotor neuropathies, cerebellar degeneration, as well as brain stem and limbic encephalopathies, often in the setting of lung malignancies (Chan et al., 2001) . We describe here a novel presentation of a small cell lung cancer ANNA-3 positive paraneoplastic syndrome consisting of lower extremity dysfunction secondary to tonically active muscles. The clinical picture was most consistent with Stiff-Person-Syndrome (SPS).
Report of a Patient
A 68 year old Caucasian male with hypertension, COPD, and a 40 pack-year smoking history presented with progressive shortness of breath, dyspnea on exertion, and lower extremity dysfunction for approximately one month. On admission, the patient noted 4 weeks of slowly progressive, severe lower extremity stiffness, an inability to stand secondary to his "feet and toes curling underneath" him, shooting pains distal to the knee brought on by movement, and very mild parasthesias distal to the ankle. Accompanying these complaints was an unintended 20 pound weight loss over a preceding 6 month period of time.
Physical examination revealed a thin, cognitively intact male with significantly increased muscle tone, especially in the lower extremities bilaterally, such that voluntary or passive dorsiflexion of the ankle was impossible. Persistence of tone was noted even while the patient was asleep. The patient also suffered from decreased muscle bulk of the arms and legs bilaterally. His muscle strength in the upper extremities was normal. In the lower extremities, his hip flexors were 4 out of 5 and knee flexors and extensors were normal power. Biceps, triceps, and brachioradialis stretch reflexes were 2 out of 4; patellar stretch reflexes were 3 out of 4 bilaterally. Plantar responses were extensor bilaterally. The patient's light touch, vibration, and pinprick sensation was mildly diminished distal to the ankles bilaterally. Peri-anal sensation was intact.
Laboratory analysis revealed normal Vitamin B12, homocysteine, ESR, HgA1C, TSH, and T4 values.
CSF analysis revealed a normal protein, glucose, and cell count. Lyme serology was negative and RPR was nonreactive. MRI of the brain revealed evidence of previous ischemic strokes involving the anteromedial left frontal lobe and the posterolateral left frontal lobe as well as a pattern of white matter change consistent with microvascular ischemia. MRI of the cervical, thoracic, and lumbar spine revealed mild multilevel disc degeneration, but no gross evidence of cord inflammation, compression, or prominent disk protrusion. EMG revealed no radiculopathies and no abnormalities localized to the peripheral motor or sensory nerves; however, EMG did reveal continuous motor unit activity of both agonist and antagonist muscles. Over the ensuing months, the patient was treated with cisplatin and etoposide for his lung cancer; concomitantly, he was treated symptomatically with oral diazepam which ameliorated some of his increased tone. With this combined therapy, the patient experienced a progressive improvement in his neurological symptoms such that at one year follow-up, his neurological examination was unremarkable and he was able to ambulate normally. Repeat imaging found no evidence of malignancy. Benzodiazepines were slowly weaned off without ill effect and the patient has remained symptom free.
Discussion
The literature describes a group of paraneoplastic antibodies referred to as anti-neuronal nuclear antibodies (ANNA-1, -2, and -3 Therefore, as the pantheon of paraneoplastic antibodies continues to increase, the prescence of a clinical paraneoplastic syndrome should prompt the search of a panel of paraneoplastic antibodies as well as any associated malignancy. As in the case discussed here, specific diagnostics and therapeutics can lead to dramatic clinical improvements.
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